NPD1 stimulation of ADAM10 coupled to suppression of BACE1-mediated Aβ42 secretion clearly warrants further study, as these dual secretase-mediated pathways may provide effective combinatorial or multi-target approaches in the clinical management of the AD process. The gene discussed is ADAM10; the disease is Alzheimer disease.